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Background: The purpose of this study is to report the efficacy of azithromycin 1.5% eye drops in children
with ocular rosacea and phlyctenular blepharokeratoconjunctivitis. This retrospective study from January 2009 to
March 2010 included 16 children treated with lid hygiene plus azithromycin 1.5% eye drops (AzyterW): 3-day
treatments (1 drop twice a day) every 10 days, reduced based on efficacy to one treatment every 15 days and
then to one treatment per month.
Results: Nineteen eyes of six boys and ten girls, aged 4 to 16 years (mean, 9.3 ± 4.0) were included. The disease was
previously resistant to lid hygiene (all the patients), oral erythromycin (one patient), and intermittent topical steroids
(six patients). The median duration of each phase of azithromycin treatment (i.e., three, two, and one treatments per
month) was 2 months. Ocular inflammation was controlled by azithromycin alone in 15 patients. In one uncontrolled
case, cyclosporine 2% eye drops was added at month 5. Bulbar conjunctival hyperemia resolved completely within
1 month in all eyes, whereas conjunctival phlyctenules and corneal inflammation took longer to improve, with a
complete resolution within 3 to 10 months. Blepharitis grade decreased from 2.31 ± 0.79 to 1.50 ± 0.73. Treatment
was stopped after a median of 6 months (from 4 to 10 months) without recurrence of corneoconjunctival
inflammation (median follow-up without treatment, 11 months). Six cases of ocular irritation were reported, two of
which led to treatment withdrawal.
Conclusion: Azithromycin 1.5% eye drops is an effective treatment for phlyctenular keratoconjunctivitis complicating
childhood ocular rosacea.
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Childhood ocular rosacea is a rare but often misdiagnosed
disorder associated with chronic blepharitis and, in
many cases, phlyctenular keratoconjunctivitis [1]. It is
alternatively named blepharokeratoconjunctivitis [2,3] or
staphylococcal phlyctenular keratoconjunctivitis. Lid
involvement is characterized by chronic posterior and
anterior blepharitis with frequent chalazia. Ocular in-
flammation is often unilateral with chronic conjunc-
tival hyperemia; phlyctenules on the conjunctiva, the
limbus, or the cornea; and inferior punctate keratopathy.
Occasionally, corneal involvement is more severe with* Correspondence: serge.doan@noos.fr
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in any medium, provided the original work is ppredominantly inferior (sub) epithelial infiltrates, stromal
ulcers, neovascularization, and scars, leading to visual se-
quelae in 17% of cases [4]. Skin involvement is inconstant.
The primary mechanism of childhood ocular rosacea is
chronic meibomitis. Staphylococcal infection in the meibo-
mian glands is probably secondary and may induce con-
junctival and corneal inflammation by a T lymphocyte
immune response against bacterial parietal antigens or
toxins. The phlyctenules and corneal infiltrates are the re-
sult of a type IV cell-mediated late hypersensitivity reaction
according to the Gell and Coombs' classification [5].
The treatment of childhood ocular rosacea is based on
its presumed physiopathogenic mechanisms and involves
improving meibomian gland function, controlling bac-
terial proliferation with lid hygiene and antibiotics, and
inhibiting T cell-mediated inflammation with topicalOpen Access article distributed under the terms of the Creative Commons
g/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction
roperly cited.
Table 1 Patient demographics and baseline characteristics
Patient no. Sex Age Unilateral Evolution
(months)
Treatment
1 F 10 Yes 96 LH
2 M 12 No 30 LH
3 F 7 Yes 15 LH + steroids
4 F 10 Yes 8 LH + steroids
5 F 7 Yes 15 LH
6 F 8 No 69 LH
7 M 15 Yes 18 LH + steroids
8 F 14 Yes 20 LH
9 F 6 Yes 10 LH + ERY
10 F 16 No 90 LH
11 M 5 Yes 12 LH + steroids
12 F 10 Yes 15 LH
13 M 5 Yes 27 LH + steroids
14 F 7 Yes 24 LH + steroids
15 M 4 Yes 20 LH
16 M 15 Yes 148 LH
LH, lid hygiene; ERY, oral erythromycin.
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stone of ocular rosacea treatment, with oral antibiotics
required in case of lid hygiene failure or in severe forms
of the disease. Second-generation tetracyclines are used
in children over 8 years old, and erythromycin,
azithromycin, or metronidazole are used in younger
patients [6-8]. Topical antibiotics are often used, but
very few publications support their efficacy [3]. Topical
steroids are very effective but should only be used in
case of acute corneal inflammation due to the risk of
iatrogenic complications. Cyclosporine 0.5% to 2% eye
drops is an interesting alternative in children with
steroid-dependent disease [9].
Azithromycin is a macrolide antibiotic characterized
by a broad antibacterial spectrum, a long half-life related
to its tissue and cell penetration [10], and anti-
inflammatory properties [11]. Oral azithromycin is an ef-
fective treatment in ocular rosacea [12] and also in cuta-
neous involvement of rosacea (with efficacy comparable
to doxycycline) [13].
In this retrospective study, we assessed the efficacy of
topical 1.5% azithromycin eye drops in children with ocular
rosacea and phlyctenular blepharokeratoconjunctivitis.
Results
Sixteen children (19 eyes) were treated: six boys and ten
girls with a mean age at initiation of azithromycin treat-
ment of 9.3 ± 4.0 years (range, 4 to 16 years).
Childhood ocular rosacea status before azithromycin
treatment
Pretreatment status is detailed for individual patients in
Table 1. The disease was asymmetric or unilateral in 13
children. Mean interval between onset of the disease and
azithromycin treatment was 39 months (from 8 months
to 12 years). Two children had ongoing recurrent
chalazia, whereas recurrent episodes of red eye were
reported in all cases. Bulbar conjunctival hyperemia and
phlyctenules were present in all eyes, and corneal in-
flammation was noted in all eyes but one. Therapy be-
fore azithromycin (which had not controlled the
inflammation) consisted of lid hygiene in all cases plus
oral erythromycin in one case and intermittent topical
corticosteroids in six cases. Topical steroids and oral
erythromycin were stopped in all cases.
Efficacy of azithromycin
The treatment and follow-up durations per patient are
reported in Table 2. Topical azithromycin was adminis-
tered for a mean of 6.0 ± 1.4 months (range, 4 to 10
months). Patients received three treatments of azithro-
mycin per month for a mean duration of 2 months
(range, 1 to 6 months), then two treatments per month
for a mean of 2 months (range, 1 to 2 months), then onetreatment per month for a mean of 2 months (range, 0 to
2 months). The disease was controlled by topical
azithromycin alone in 15 out of 16 patients (18 eyes).
The remaining patient (one eye) required the addition of
cyclosporine 2% eye drops for 5 months after 5 months
of azithromycin in order to control ocular inflammation.
Topical azithromycin dramatically improved ocular red-
ness (reported by the patient) and bulbar conjunctival
hyperemia (assessed by the ophthalmologist), both of
which resolved within 1 month in all eyes (Figure 1A).
Conjunctival phlyctenules and corneal inflammation took
longer to improve, with a complete resolution within 3 to
10 months (Figure 1B,C). Inferior superficial punctate
keratitis only partially resolved in all eyes.
Blepharitis grading was available in 13 patients (16 eyes).
Mean grade decreased from 2.31 ± 0.79 at baseline to 1.50
± 0.73 at the end of the treatment. Although anterior and
posterior signs of blepharitis were not graded separately,
anterior blepharitis seemed to improve more significantly
than posterior blepharitis and meibomian gland dysfunc-
tion. However, no episodes of chalazion were noted during
azithromycin treatment, even in the two children who
complained of recurrent chalazia at baseline.
Azithromycin was stopped when conjunctival phlycte-
nules and corneal inflammation had completely resolved,
which occurred after a mean of 6.0 ± 1.4 months (between
4 and 10 months). Corneoconjunctival inflammation did
not recur with lid hygiene alone after a mean follow-up of
11.0 ± 1.7 months (8 to 14 months).
Table 2 Treatment, follow-up duration, and adverse events







1 LH 6 8
2 LH 4 9
3 LH 6 12 Moderate ocular redness upon instillation
4 LH, topical cyclosporine added
at month 5 for 5 months
10 11 Important burning, treatments stopped at
month 10
5 LH 6 9 Mild stinging upon instillation
6 LH 5 13
7 LH 6 9
8 LH 8 12
9 LH 4 10 Mild stinging upon instillation
10 LH 6 11
11 LH 6 9
12 LH 6 12 Moderate ocular redness upon instillation
13 LH 6 10
14 LH 6 11
15 LH 6 12
16 LH 5 14 Important burning, treatment stopped at month 5
LH, lid hygiene.
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Adverse events are summarized in Table 2. Mild
sensations of ocular stinging upon instillation were
reported in two patients and moderate ocular redness
after instillation in two other cases. Treatment was
stopped because of local intolerance (significant sensa-
tion of burning) in two other patients after 5 and 10
months. As the disease was already controlled for
these last two patients, no recurrences were observed
after azithromycin was withdrawn. No systemic adverse
events were reported by the parents.
Discussion
Childhood ocular rosacea is believed to be the conse-
quence of chronic meibomian gland dysfunction. Sec-
ondary staphylococcal infection of the lid margin is
often present and is probably responsible for the
corneoconjunctival inflammation by means of an im-
munological specific T cell response. This combined
mechanism explains the efficacy of both topical anti-
inflammatory drugs (steroids or cyclosporine) and sys-
temic antibiotics such as macrolides or tetracyclines.
Azithromycin is a new treatment option for cutaneous
rosacea and seems to be as effective as tetracyclines [13],
and its efficacy in treating ocular rosacea has been
demonstrated when administered orally [12].
Azithromycin eye drops are now available for the treat-
ment of bacterial conjunctivitis, and in this indication,
azithromycin 1.5% eye drops given twice daily for 3 daysis as effective as tobramycin 0.3% eye drops four times a
day for 7 days [14].
Our study showed that topical azithromycin 1.5% is a
very effective treatment of ocular rosacea in children. Its
efficacy on conjunctival and corneal inflammation is re-
markable. However, because of the delayed action on cor-
neal inflammation, prior clinical experience has shown
that very severe cases with vision threat should be con-
comitantly treated with topical steroids and/or cyclospor-
ine. Oral erythromycin is usually prescribed in childhood
ocular rosacea [15]. In this study, in one patient who had
been unsuccessfully treated with oral erythromycin, re-
placement by azithromycin resulted in a complete con-
trol of inflammation. Our previous treatment strategy
was to use oral erythromycin as a first-line treatment in
combination with lid hygiene. However, our early experi-
ence with topical azithromycin showed us that this local
treatment was superior to systemic erythromycin. This is
why we decided to use, since then, topical azithromycin
as a first-line therapy. Topical azithromycin has several
advantages over oral antibiotics. Azithromycin has a very
long half-life, with significant tissular accumulation and
concentrations. In a rabbit model, after administration of
1% azithromycin ophthalmic solution, significant con-
centrations are detected in the tears, conjunctiva, cornea,
and lids for as long as 6 days in the lids [10]. Concen-
trations in the tears, conjunctiva, and cornea remained
above minimal inhibitory concentrations for respectively
7, 17, and more than 24 days after instillation of AzyterW
Figure 1 Improvement of bulbar conjunctival hyperemia,
conjunctival phlyctenules, and corneal inflammation with
azithromycin treatment. (A) Evolution of bulbar conjunctival
hyperemia (number of eyes). (B) Evolution of conjunctival
phlyctenules (number of eyes). (C) Evolution of corneal inflammation
(number of eyes).
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day (bid) for 3 days [16]. This is why we chose a discon-
tinuous treatment regimen which was very simple for the
patients; one treatment corresponds to one box of eye
drops, and so the initial scheme of three treatments per
month tapered to two and then one per month was con-
venient, easy to understand, and well accepted by the
children and their parents. The initial dosing (3 days
three times monthly) was chosen because of the 7-day
persistence of azithromycin in the tears. The tapering
scheme was chosen empirically. Oral erythromycin has
to be taken twice daily for a continuous period of several
weeks. In the 16 patients studied, topical azithromycin
did not induce systemic side effects, whereas oral
erythromycin frequently induces gastrointestinal
troubles. Oral metronidazole has also been proposed as a
treatment for ocular rosacea, but while it seems to be an
effective treatment, the fact that short-course therapy is
required in order to avoid peripheral neuropathy may re-
sult in more frequent relapses [6].
Few publications reported the efficacy of topical
antibiotics in this disease. In a retrospective study by
Viswalingam et al., topical chloramphenicol eyedrops
four times daily for 1 month and chloramphenicol oint-
ment at night for 4 months were successfully prescribed
in mild to moderate cases [3]. Azithromycin ophthalmic
solution 1% has been evaluated in posterior blepharitis
in adults in two small studies [17,18]. In one study,
meibum quality and lid margin redness improved more
in patients treated with lid hygiene and azithromycin for
2 weeks than in controls treated with only lid hygiene.
In the second study, symptoms, meibum quality, and lid
margin redness improved after treatment with lid hy-
giene and azithromycin for 4 weeks. While we did not
specifically analyze the posterior lid margin in our study,
the effect of topical azithromycin on anterior blepharitis
was noticeable, and no chalazia were noted.
Topical steroids are frequently prescribed in chil-
dren with ocular rosacea and phlyctenular blepharo-
keratoconjunctivitis, but relapses occur after the end of the
treatment in up to 40% of cases [15]. Treatment duration
is a key element for avoiding recurrences. In our study,
treatment was stopped after 4 to 10 months, and no recur-
rence was observed during a median follow-up of 11
months (8 to 14 months). Long-term treatments are usu-
ally required to control the inflammation. A complete dis-
appearance of the phlyctenules and corneal infiltrates is
necessary before stopping the treatment, which was
attained in 3 to 6 months in the majority of children
included in this study with topical azithromycin. This min-
imal treatment duration is comparable with topical cyclo-
sporine [9] or topical chloramphenicol [3]. Such duration
is not acceptable with topical steroids because of the risk
of ocular complications. In our series, topical steroids were
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prescribed, and none of the patients required additional
steroid therapy thereafter.
In a previous study, we showed that topical 2% cyclo-
sporine is a very potent treatment of phlyctenular
blepharokeratoconjunctivitis [9]. The efficacy of topical
azithromycin was sufficient in most cases, but as clinical
experience indicates that topical cyclosporine may have
greater efficacy, patients with very severe corneal inflam-
mation were prescribed topical cyclosporine as first-line
treatment.
A biphasic effect was observed in this study. The ef-
fect on ocular redness was very fast, within a month,
whereas phlyctenules and corneal infiltrates took sev-
eral months to heal. This may point to different
mechanisms. Ocular redness might be related to bac-
terial toxin production. Phlyctenules and corneal
infiltrates are thought to be caused by a type IV cell-
mediated delayed hypersensitivity reaction against parietal
staphylococcal antigens [5]. In addition to its antibiotic ef-
fect, azithromycin also has anti-inflammatory effects.
Indeed, it has been shown to reduce the production
of the pro-inflammatory cytokines IL-12 and IL-6 by
macrophages in vitro [11]; to suppress matrix
metalloproteases 2 and 9, nuclear transcription factor
NFkB, and Toll-like receptor 2 in corneal epithelial
cells in vitro [19,20]; and to inhibit macrophage and
dendritic cell migration after corneal burn in a
mouse model [21].
The safety profile of topical 1.5% azithromycin seems
good in children suffering from ocular rosacea. Discon-
tinuous treatment with topical 1.5% azithromycin was
well tolerated. Local intolerance was seen in a small
number of cases and was usually mild, except in two
patients who stopped the treatment after 5 and 10 months,
respectively. Comparable side effects have been reported in
the literature [17,18].
The main limitation of our study is the small number
of patients, but rosacea in children is infrequent, and the
largest series published to date included 44 children [3].
The retrospective nature of this study is also an im-
portant limitation. A multicenter prospective con-
trolled study should be the next step for evaluating
azithromycin eyedrops in childhood ocular rosacea.
Conclusion
In conclusion, this retrospective study showed that top-
ical 1.5% azithromycin eye drops is an effective and safe
treatment in non-severe forms of childhood ocular ros-
acea with phlyctenular blepharokeratoconjunctivitis.
When treated under a discontinuous but prolonged regi-
men for at least 4 months, recurrences did not occur up
to 14 months after the end of treatment. Considering
the benefits/risk ratio, this new treatment could probablyreplace oral antibiotics in this disease, but further con-
trolled studies are required.Methods
Design
This is a retrospective, non-comparative, interventional
case series.Methods
We reviewed the files of all 16 consecutive children with
rosacea and phlyctenular blepharokeratoconjunctivitis who
were treated with topical 1.5% azithromycin eye drops be-
tween January 2009 and March 2010 in the Department of
Ophthalmology at Bichat Hospital and Fondation A. de
Rothschild, Paris, France. Written informed consent was
obtained from the patients and from their parents for pub-
lication of this report. This study was approved by the Eth-
ics Committee of Foundation A de Rothschild.Treatment strategy
Patients presenting with ocular rosacea were initially
treated with lid hygiene once daily, and frequent normal
saline instillations were initially prescribed alone for at
least 1 month. Patients with sight-threatening corneal
infiltrates approaching the visual axis were treated with
steroids and cyclosporine 2% eye drops and were not
treated with azithromycin; therefore, they were not
included in the study.
Azithromycin 1.5% eye drops (AzyterW, Thea Laborator-
ies) was administered only to patients who did not respond
to lid hygiene. A three-day treatment (1 drop bid) was ini-
tially prescribed every 10 days (i.e., three treatments
monthly) for at least 1 month. According to clinical effi-
cacy, treatment was tapered to one treatment every 15 days
and then one treatment monthly.Follow-up
Patients were examined after 1 month and every 1 to 2
months thereafter.
The main outcome measures were ocular redness
(reported by the patients), occurrence of chalazia (reported
by the patients), conjunctival bulbar hyperemia, conjunc-
tival phlyctenules, corneal inflammation (phlyctenules and
infiltrates) and epitheliopathy, and lid margin inflammation
(blepharitis). All measures were graded on scales of 0 to 4.
Ocular rosacea was considered to be controlled if all items
except lid margin inflammation had a score of 0. Ocular
and systemic adverse events were also reported.
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